In this special episode of SpreadLove in Organizations, produced in partnership with the MIT Club of Boston BioSummit, Naji Gehchan welcomes Dimitrios Skaltsas, CEO and co-founder of Intelligencia AI. Founded in 2017, Intelligencia is a pioneer in applying artificial intelligence, data science, and biomedical expertise to transform decision-making in pharmaceutical R&D. Dimitrios shares his remarkable journey from studying law in Greece to leading one of the most innovative companies in healthcare AI. Inspired by his roots and driven by a deep sense of purpose, he reflects on the pivotal moments that shaped his career — from consulting at McKinsey to discovering a passion for innovation in life sciences — and how love, family, and giving back have guided his mission. Dimitrios dives into the origins of Intelligencia AI and the crucial problem it set out to solve: improving R&D productivity and redefining how risk is assessed in drug development. By building machine learning models to predict the probability of clinical success, Intelligencia provides pharmaceutical companies with a robust decision-support tool, helping them prioritize programs, optimize portfolios, and ultimately bring new therapies to patients more effectively. Dimitrios emphasizes that AI should complement, not replace, human judgment, serving as a powerful tool to support intuition with data-driven insights. As the company continues to grow, it is expanding into new therapeutic areas, geographies, and functionalities, with a focus on making drug development smarter, faster, and more predictive. The conversation also explores the human side of leadership and innovation. Dimitrios shares how his love of painting — from abstract canvases to portraits of people he knows - mirrors his leadership philosophy: balancing big-picture creativity with deep human connection. He defines leadership as a responsibility to serve others and sees clinical trials as both a blessing and a challenge; essential for patient safety but ripe for innovation. On AI, he is optimistic yet cautious, recognizing its transformative potential alongside its risks if not guided by ethics and discipline. This episode offers a rich exploration of purpose-driven leadership, the intersection of art and science, and the future of AI in reshaping how life-changing medicines are discovered and developed. "AI is a huge opportunity for life sciences, but without ethics, it can mislead us." MEET OUR GUESTS Ditrios Skaltsas Co-Founder & CEO, Intelligencia AI. As the CEO and co-founder of Intelligencia AI™, Dimitrios Skaltsas drives the AI-driven technology organization's business and investment growth strategy while overseeing critical functional areas of the multidisciplinary global team. Founded in 2017, Intelligencia AI leads the way in leveraging proprietary data, biomedical expertise and artificial intelligence (AI) with its patented technology to address significant challenges in the pharmaceutical industry. These challenges include lengthy drug development timelines, excessive costs, and unsustainable return on investment (ROI). Its suite of AI-powered solutions delivers actionable insights crucial in mitigating risks and enhancing decision-making associated with drug development by providing an accurate, unbiased assessment of a drug’s probability of success.  In 2024, the company received a U.S. patent for its accurate and transparent probability of drug success assessments. It also earned its inaugural spots on the Inc. Regional (Northeast) and Inc. 5000 for the first time. The Healthcare Technology Report recognized it as one of the Top 100 Healthcare Technology Companies. In 2021, the company completed its Series A funding and was named one of Forbes's Top AI Companies to Watch. During this time, Dimitrios played a pivotal role in establishing a strategic partnership with ZS, a global professi

In this episode of SpreadLove in Organizations, I am joined once again by my longtime friend and colleague, John Bamforth, to celebrate the launch of his new book Race to Innovation. John’s remarkable journey has taken him from his roots in Wigan, England, to building global brands at Eli Lilly, and most recently, leading the Eshelman Institute for Innovation at UNC-Chapel Hill. He was my very first guest when I started this podcast four years ago, and it’s a joy to welcome him back as we reflect on his career, his growth, and the bold ideas he is now championing. John shares the story behind Race to Innovation, which highlights the often-overlooked history of innovation and entrepreneurship in marginalized communities, particularly African American communities. The book blends untold stories of past trailblazers with interviews of today’s innovators, all grounded in the belief that unlocking potential in underrepresented groups creates value for all of us. This is not a zero-sum game; rather, encouraging diversity of thought and entrepreneurship helps societies thrive together. Our conversation goes beyond the book, touching on the meaning of innovation, the intentionality required to build diverse, trusting teams, and the essential role of purpose in uniting people around bold goals. John’s insights remind us of the power of assuming potential in every individual and of leading with genuine care for one another. His vision is a hopeful call to see difference not as division but as a force for solving the world’s most pressing challenges - together. "Innovation starts with assuming potential in every individual - and unlocking it benefits us all." MEET OUR GUESTS John P Bamforth, independent Director for Humacyte and a member of the commercialization committee. Dr John Bamforth PhD is an independent director for Humacyte Inc (NASDAQ: HUMA) and a member of the commercialization committee. In addition, he has served on the Boards of the Structural Genomics Consortium (https://www.thesgc.org) and READDI (https://readdi.org). On the READDI Board, John recruited 4 independent Board members including Sen Richard Burr and Lydia Ogden PhD (JNJ) and he chairs the compensation committee. He is an advisor to several privately owned biotech and healthcare companies and is an active investor. John is co-founder of the B and M Impact Foundation (BMimpact.org) which is focused on creating wealth and health in disadvantaged communities. John had a 30-year career at Eli Lilly and Company culminating in the Chief Marketing Officer (CMO) role from 2016 to his retirement in 2018. He was also CMO of Lilly's $10B US operation from 2012-2016. Over his career at Lilly John was known for building highly engaged teams and launching multiple brands across the globe. Probably, his best-known success was the building of Cialis globally, the $2B a year blockbuster brand. On his retirement from Lilly, John was hired to lead Eshelman Innovation at the University of North Carolina, Chapel Hill, an institute that was founded by a $100M gift, the largest gift in UNC's history. The institute leverages industry practices and the University's $1.5B research enterprise to develop novel therapeutics alongside digital health technologies. He stepped down from the role in 2025 after 6 years to focus on his board work and philanthropic endeavors. John has a pharmacy degree and PhD from his education in the United Kingdom. Pharmavoice named John one of Pharma's top 100 'Inspirational Leaders' in 2007 and his alma mater, Aston University, awarded him an Honorary Doctorate for service to the Pharma Industry in 2012. John lives in Chapel Hill, North Carolina with his wife Sue, and has two adult children, Thomas and Rebecca. More about the Book on this link!

In this special episode of SpreadLove in Organizations, I had the honor of hosting Dr. François Nader and Khalil Barrage, the visionary co-founders of BioLink. This New York–based nonprofit is on a mission to connect biosciences professionals of Lebanese origin around the world, while building a sustainable life sciences ecosystem in Lebanon. François shared his inspiring journey from physician in Lebanon to global biotech leader, including turning around NPS Pharma before its $5B acquisition by Shire. Khalil reflected on his path from Lebanon to becoming one of the most active biotech investors through The Invus Group, with landmark investments in companies such as Moderna. Both leaders opened up about the origins of BioLink, which were born out of tragedy but fueled by hope. In the aftermath of the Beirut port explosion, they witnessed the strength and generosity of the Lebanese diaspora in the life sciences community. This moment of crisis revealed an incredible network of Lebanese talent across the industry and sparked the idea to create a global platform. BioLink was established not only to bring these leaders together, but also to lay the foundation for a life sciences economy in Lebanon that can create opportunities for the next generation. Throughout our conversation, François and Khalil emphasized values of vision, resilience, and credibility in leadership. They reminded us that true leadership shines in times of crisis, and that success in biotech requires grit, integrity, and long-term commitment. Above all, they shared a dream: to harness the collective power of Lebanese professionals worldwide to contribute back to Lebanon and build something enduring. This episode is a testament to purpose-driven leadership, collaboration, and the belief that together, we can inspire change. "Leaders show the most leadership during a crisis." -François Nader "In biotech, there are no shortcuts — integrity and the right team matter.” - Khalil Barrage MEET OUR GUESTS Francois Nader chairman of GEn1E Lifesciences, and board director of Moderna and Ring Therapeutics. MEET OUR GUESTS Khalil Barrage Managing Director at The Invus Group. This is a special episode, the first of a series in partnership with Biosciences Lebanese International Network – BioLink. This New York-based non-profit is on a mission to build a global community of professionals in biosciences of Lebanese origin, like me, and it turns out, there’s quite a few of us. Most interestingly, it has set a bold vision, which is to catalyze a life sciences ecosystem in Lebanon by working with local talent and academic centers, with the support of the Lebanese diaspora community. This is an ambitious goal, but BioLink.org’s founders Dr. Francois Nader and Khalil Barrage are some of the most accomplished people in the industry, and if anyone can pull it off, they can. I’m thrilled to have them with me today! Francois is a pharma veteran who sits on the board of several biopharma companies. He is chairman of GEn1E Lifesciences, and a board director of Moderna and Ring Therapeutics, as well as a senior advisor to Blackstone Life Sciences. Francois became well known within the industry, when he took the helm of NPS Pharma in 2006. The company was then on the verge of insolvency. Francois turned it around and sold it less than a decade later for more than $5 billion to Shire.  Khalil is a managing director at The Invus Group, a New York-based global investment firm. He established the Public Equity Group which invests in emerging innovative biotech companies, and co-manages private biotech investments, making Invus one of the most active investors in biotech, according to PitchBook. Khalil also sits on the board of several biotech companies, including ElevateBio, Sensorion, Onxeo, Protagenic Therapeutics, and Orthobond.

In this episode of Spread Love in Organizations, Naji Gehchan had the pleasure of hosting Catharine Smith, the inaugural Executive Director of the Termeer Institute. The Institute honors the legacy of former Genzyme CEO Henri Termeer by supporting biotech leaders who are driven by patient impact. Catherine shared her powerful journey, from growing up with limited access to healthcare, to leading initiatives at the Clinton Foundation and Harvard, and now shaping a movement that empowers early-stage biotech CEOs to tackle some of healthcare’s biggest challenges. Her personal story, rooted in seeing healthcare as a human right, set the stage for our inspiring conversation. Throughout our discussion, Catherine highlighted the importance of leadership as a catalyst for systemic change. Drawing from her experience in hospital medicine, primary care, and crisis response, she emphasized that effective leadership goes beyond technical expertise —it’s about training, mentoring, and empowering people to drive meaningful improvements in patient care. At the Tamir Foundation, this philosophy translates into supporting biotech founders not only with resources and technical skills, but also with values-aligned networks, mentorship, and leadership development tailored to their journeys. Catherine also shared her perspective on the future of biotech as a powerful lever for change in healthcare. From the promise of rare disease therapies to the growing energy in women’s health, she stressed how science and innovation must be matched with responsibility, equity, and human-centered leadership. For her, the “human variable” is the most crucial factor in whether breakthroughs succeed in transforming lives. As we closed, Catherine reminded healthcare leaders to hold onto their “why,” seek partnerships, and focus on solving big problems together. It was a conversation full of hope, responsibility, and a call to action for leaders across healthcare and biotech. "Biotech can be a lever to change healthcare." MEET OUR GUEST Catharine Smith, Executive Director of the Termeer Institute. Catharine Smith serves as inaugural Executive Director of the Termeer Institute (Former Termeer Foundation), which carries on the bold legacy of former Genzyme CEO Henri Termeer, who was committed to mentoring emerging leaders and whose dedication to patients resulted in groundbreaking treatments for rare diseases. The Termeer Foundation understands that bringing new treatments to patients is grueling work with a low probability of success and believes we can improve these odds by positively impacting the human variables in healthcare. By supporting biotech leaders, the Foundation seeks to increase the probability of creating cures and solving healthcare’s greatest challenges. Prior to the Termeer Foundation, Catharine served as the CEO of the Clinton Health Matters Initiative at the Clinton Foundation where she led a team focused on stigma reduction and overdose prevention related to the opioid epidemic. Before that role, Catharine was the Executive Director of the Harvard Center for Primary Care where she led business development, strategy, and operations for a think-tank focused on improving value-based, patient-centered care. Catharine holds a master’s degree in business administration from the Massachusetts Institute of Technology and a graduate degree in social science research from the University of Chicago.

In this episode, Naji Gehchan welcomes Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company using AI and data-driven solutions to expand access to cancer clinical trials. Selin shares her personal journey from a structured career in engineering and private equity to founding Massive Bio after her family’s experience with cancer. What started as a side project quickly became her full-time mission, as she realized the immense challenges and dedication required to drive change in healthcare. Since 2015, she has led Massive Bio to impact over 160,000 patients worldwide, with a focus on underserved communities and equitable access to clinical trials. Selin highlights the importance of applying engineering principles to clinical operations, particularly in solving the long-standing challenge of patient recruitment in oncology trials. By combining systematic problem-solving with regulatory knowledge, Massive Bio addresses inefficiencies across the patient enrollment journey—identification, pre-screening, and last-mile enrollment. She explains how AI enables scalability, reducing the time it takes to match patients with clinical trials from months to minutes. This approach not only empowers patients to advocate for themselves but also helps physicians and pharma companies accelerate drug development, creating both individual and population-level impact. Discussing leadership and growth, Selin emphasizes resilience, teamwork, and the importance of early adopters in driving healthcare innovation. She speaks candidly about the challenges women face in senior roles within health tech and the need for true meritocracy. At Massive Bio, she fosters a flat, mission-driven culture where every team member feels empowered and connected to the purpose of improving patients’ lives. Her closing advice to healthcare leaders is to remain resilient, embrace humility, and stay grounded—focusing on what truly matters: health, team, and impact. "I’m not seeking fairness in life, but success in the unfairness of life." MEET OUR GUEST Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions. Selin Kurnaz is the CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions. She holds a PhD in Mechanical Engineering and brings over a decade of experience in life sciences strategy and operations. Inspired by her family’s cancer journey, Selin launched Massive Bio in 2015 to make cutting-edge treatments more accessible, particularly in underserved communities. Under her leadership, the company has onboarded over 160,000 patients and built a global network of sites, partners, and advocates. Selin is also a recognized voice for women in tech and digital health innovation. About Massive Bio: Massive Bio is a healthcare technology company using AI to match cancer and rare disease patients with clinical trials and optimize drug use for better outcomes. Founded to address the barriers patients face in accessing advanced treatments, the platform simplifies and personalizes the clinical trial journey. With over 160,000 patients onboarded and partnerships with top pharma companies across 17 countries, Massive Bio is transforming oncology care. Its solutions reduce inefficiencies, accelerate drug development, and improve treatment access globally. The company is now expanding beyond trial matching into broader oncology services to become a leading data-driven cancer care platform.

In this episode of Spread Love in Organizations, Naji Gehchan welcomes Christy Fernandez-Cull, CEO of DaVinci Wearables and a trailblazer in tech and health innovation. Christy shares her inspiring journey from childhood curiosity — designing a cereal dispenser to let her hardworking parents sleep in — to leading groundbreaking work at companies like Apple, Waymo, and Google. With a PhD from Duke and an MBA from MIT, Christy blends deep technical expertise with visionary leadership, always guided by a moral compass instilled by her family and a relentless curiosity about the world. Christy introduces her current venture, DaVinci Wearables, with the bold ambition of becoming the “body API for better health.” She describes a future where garments not only clothe us but also provide real-time biometric insights, especially focused on women’s health, a historically underserved field. With partnerships across universities and health systems, DaVinci is building a wearable ecosystem that tracks hydration, hormones, nutrition, and physical activity, empowering users through a smart companion app that educates and nudges healthier habits. Their unique platform blends data, personalized coaching, and community, aiming to democratize body intelligence for every stage of a woman’s life. Throughout the conversation, Christy speaks candidly about the challenges and joys of entrepreneurship, especially as a female founder in health tech. She emphasizes the importance of empathy — both toward others and oneself — and encourages founders to stay anchored in purpose by connecting directly with the people they serve. Christy’s reflections on leadership, equity in women’s health, and the role of love and service in organizations offer powerful inspiration for healthcare leaders seeking to drive meaningful change. "If you need to feel inspired, go directly to your customer… They’ll remind you why you started." MEET OUR GUEST Christy Fernandez-Cull, CEO of DaVinci Wearables and former leader of sensing teams at Waymo (Google Self-Driving) and Lyft's Self-Driving Division. Dr. Christy Fernandez-Cull is CEO of DaVinci Wearables and former leader of sensing teams at Waymo (Google Self-Driving) and Lyft's Self-Driving Division. She played a key role at Apple, contributing to autonomous systems and releasing the first LiDAR module in the 2020 iPad. Dr. Fernandez-Cull has experience in Defense technologies at MIT Lincoln Laboratory and consumer products at Apple. She advises VCs and startups in mobility, autonomous vehicles, and digital health, and serves on several boards. She holds a Ph.D. from Duke University and an MBA from MIT and lectures at Columbia University and MIT. Longer Dr. Christy Fernandez-Cull is the CEO of DaVinci Wearables. Previously, she led the sensing and perception system’s teams at Waymo - formerly Google Self-Driving. She was also the Head of Sensors at Lyft Level 5 Self-Driving Division, leading sensor architecture for Lyft vehicle platforms — designing machine eyes to help transform transportation of the future. Prior to Lyft, she was a senior technologist at Apple spanning autonomous systems and the Camera and Depth Hardware team that released the first-of-kind Light Detection and Ranging module in the 2020 iPad. She has spanned both the development of Defense technologies at MIT Lincoln Laboratory and at-scale consumer-product technologies at Apple. She is a senior science advisor to multiple VCs and startups in the areas of sensors and systems for mobility applications, autonomous vehicles and digital health and wearables. She’s a Board member of Omnitron and a Venture Partner and Deep Tech Advisor at L’attitude Ventures and serves on a non-profit board. She received her MS and Ph.D. in Engineering from Duke University and MBA from MIT and enjoys mentoring in STEM/STEAM fields and serves as a adjunct/lecturer at Columbia University, guest lecture and AI practitioner at MIT-LL and MIT Media Lab.

In this episode of Spread Love in Organizations, I had the pleasure of hosting Michael Pietrack, a seasoned recruiter in the pharmaceutical industry with nearly two decades of experience. Michael shared his fascinating journey, starting as a college baseball coach and transitioning into pharmaceutical recruiting by chance. Over the years, he has placed more than a thousand professionals, making a significant impact on the industry by connecting top talent with critical roles in medical affairs and beyond. Michael’s commitment to improving healthcare by enabling the success of industry leaders was evident as he discussed how recruiting for this field has become a purposeful mission for him. Michael offered invaluable advice for both hiring managers and job seekers. For hiring managers, he emphasized the importance of clarity in defining roles, avoiding the pitfall of hiring clones, and trusting one’s gut instinct when making decisions. For candidates, he highlighted the need to have a clear career strategy, prioritize the “people” factor when considering opportunities, and be willing to take risks for growth. Michael also shared insights from his podcast, The PharmaVerse, where he explores leadership across the pharmaceutical universe. One key takeaway from his interviews is the central role of genuine care in effective leadership—a value deeply aligned with our podcast’s focus on spreading love in organizations. "Leadership is leading from the front while ensuring no one is left behind." MEET OUR GUEST Michael Pietrack Practice Lead for Pharma and Biotech recruiting team at Kaye/ Bassman International Corp. Michael Pietrack has been recruiting in the Pharmaceutical Industry for nearly 20 years. He and his team have successfully placed more 1,000 Pharmaceutical professionals during that time, leaving a positive impact on the industry. Michael started his recruiting career with The Alpine Group, where he led the Medical Affairs Search Practice. In 2015, Michael co-founded TMAC Direct, an executive search firm exclusively devoted to Medical Affairs. Under Michael’s leadership, TMAC Direct was named one of the Top US Executive Search Firms by Forbes. In 2023, Michael joined Kaye/Bassman to lead the expansion of the already established and high-performing Pharmaceutical and Biotechnology Search Practice. Aside from recruiting, Michael is also a speaker, recruiting trainer, and an accomplished author and was recognized as one of Pharma’s 100 Most Inspiring People by PharmaVoice. Michael is also a fellow podcast host on The Pharamaverse Podcast, where he engages in insightful conversations with industry leaders. 

On this episode, I had the privilege of hosting Afarin Bellisario, a mentor at MIT Sandbox, author, and tech entrepreneur with an extraordinary life story. Afarin began by sharing her journey from her childhood in Iran to becoming a prominent figure in high-tech and entrepreneurship in the U.S. Growing up in a family that straddled traditional and modern Iran, she had a unique perspective on navigating the contrasting worlds of South and North Tehran. Her education, initially rooted in mathematics, became her ticket to freedom and opportunity, culminating in her studies at NYU and MIT. The tumultuous events of the Revolution profoundly shaped her, compelling her to forge a new path in America. She eloquently described how curiosity, resilience, and adaptability fueled her career, whether in corporate America or mentoring young entrepreneurs. We also delved into her debut novel, Silence Whispers, which tells the story of a young woman navigating transformative changes in her life and country. Afarin explained how this fictional character, Gohar, was inspired by both her own experiences and the rich stories of her heritage, blending historical and personal elements. Through extensive research and creative writing, she captured the complex dualities of Iranian society and the broader universal struggles of identity, resilience, and transformation. Afarin emphasized that while Gohar shares some traits with her, the character stands apart as a vehicle for exploring the broader human experience. The novel serves as both a personal exploration and a reflection on the cultural and societal shifts of her homeland. Finally, Afarin shared her philosophy on the intersection of history and technology, emphasizing how understanding the past can inform and guide our technological future. Drawing on examples from her work with startups and historical case studies, she highlighted the recurring patterns in how society reacts to radical new technologies. From the advent of radio to the rise of artificial intelligence, Afarin underscored the importance of maintaining human agency and using technology as a tool for good. Her reflections offered profound insights into leadership, innovation, and the enduring need to balance progress with humanity. "Change is inevitable; embracing it with curiosity turns challenges into opportunities." MEET OUR GUEST Afarin Bellisario Consultant, Advisor at MIT, and Author. Afarin Bellisario bridges East and West, technology and the human condition, and past and present. Born and raised in Tehran in a family with its feet in the past and its head in the future, she led a successful career in high-tech and international business in the US after earning her PhD (from Massachusetts Institute of Technology (MIT). But writing had always been her passion. Having written professionally in pre-revolutionary Iran, she has published op-eds in major papers, including the Boston Globe and an essay, Movies with my Aunt, as part of the anthology Love & Pomegranates.  Today, she mentors startups, teaches, and writes about the clash between tradition and modernity and how the past can shed light on our technology-fueled future. A music lover, she is a Cambridge Chamber Ensemble board member and writes for their newsletter as well as on Medium. Afarin continues to discover new destinations globally.

In this episode of SpreadLove in Organizations, Naji hosted Jason Bhardwaj, a seasoned life science executive and CEO of Nova Anchora. Jason shared his journey from growing up in a science-oriented household to leading biotech startups. He described how his passion for healthcare and business developed through his studies in biomedical engineering at Duke and a decade-long career in consulting. His transition from consulting to entrepreneurship reflects his drive to build impactful solutions in heatlthcare. Jason highlighted key lessons from his experience building and leading biotech teams. He emphasized the importance of finding personal gratification in the startup ecosystem, where milestones - like moving a project from concept to clinic - feel profoundly rewarding. He discussed the critical role of people decisions in virtual biotech models, stressing the importance of rigorous hiring processes and selecting the right partners to ensure a cohesive and capable core team. Jason's philosophy centers on creating an environment where each team member's unique skills contribute to breakthrough innovations. Beyond biotech, Jason shared his commitment to community and education. With two young children, he recently announced his candidacy for the Newton, Massachusetts public school committee. Inspired by a family legacy in teaching, he aims to contribute to educational development and support local families. This passion underscores his belief that learning is a lifelong journey, whether in science, business, or public service. "Find the way you want to make a difference" MEET OUR GUEST Jason Bhardwaj CEO of Nova Anchora. Jason Bhardwaj is an experienced life sciences executive with a broad background leading in startups and ~20 years working in healthcare. Currently, Jason is the CEO of Nova Anchora, developing a recombinant protein-based treatment for DEB (dystrophic epidermolysis bullosa). Prior to this, Jason served for 6 years as CEO of another dermatology-focused biotech (Follica, a drug-device combination product for alopecia). Jason has led or advised across a wide range of technologies (drugs, devices, combinations), as well as indications (e.g., Dermatology, Psychiatry, Cardiology, Ophthalmology). Prior to life science startups, Jason studied biomedical engineering (Duke), received a masters degree in business (Harvard), and developed a decade of foundational experience in consulting (Bain) working with some of the largest healthcare innovators on a full functional suite of critical challenges (e.g., growth strategy, pricing, M&A diligence, organizational and operating model alignment). Jason and his family live in Newton, MA, where he is involved in the community as a soccer coach, marathon runner, and most recently via a bid for the school committee. Find more and support Jason's mission: www.jason4newton.com

In this episode, Naji engages in a deep conversation with Angela Justice, an award-winning Chief People Officer, executive coach, and neuroscientist. Angela shares her journey from consultant to Chief People Officer and founder of Justice Group Advisors, providing unique insights from her extensive experience in healthcare, biotech, and nonprofits. Angela’s curiosity about human behavior, which began with her passion for dance, has driven her to explore the concept of potential in individuals and teams. She discusses how her lifelong fascination with understanding people’s motives and capacities fueled her career in executive coaching, where she helps leaders identify and maximize their strengths while fostering strategic alignment in organizations. Angela emphasizes the power of purpose-driven leadership and the importance of aligning individual motivations with organizational goals to cultivate high-performing teams. She shares that one of the most vital aspects of leadership is focusing on a larger purpose, especially in healthcare, where the mission centers on improving patient lives. In her view, humility is essential for leaders, allowing them to embrace diverse ideas and remain open to learning from their teams. Angela believes that fostering an environment of collaboration and unity around shared goals can significantly enhance both individual and team performance, driving sustainable success in organizations. Angela also speaks about her journey in embracing her unique strengths, or “edge,” which she describes as critical to thriving in one’s career. She encourages leaders and professionals to discover what makes them unique and leverage that distinctiveness as a strategic advantage. "Move up in your life, not just in your career. Think bigger about the legacy you want to leave, and you’ll bring more impact to the world." MEET OUR GUEST Angela Justice Chief People Officer, executive coach, and trusted advisor. Angela Justice is an award-winning Chief People Officer, executive coach, and trusted advisor to top executives. A neuroscientist by training, Angela began her career as a management consultant at McKinsey & Company before holding senior leadership positions in Medical Affairs, Patient Advocacy, and Human Resources. Most recently, she was the Chief People Officer and Head of Medical Affairs at TCRTherapeutics. Angela's diverse background and hands-on experience in the C-suites and boardrooms of healthcare, biotech, and nonprofit sectors provide her with a unique and informed perspective. Her deep understanding of human and organizational behavior enables her to drive sustainable change, helping leaders establish strategic alignment, address blind spots, and leverage strengths for exceptional results. As the Founder and Managing Director of Justice Group Advisors, Angela is dedicated to helping leaders earn and embrace their seat at the table. You can download here the workbook to find your edge! Thank you Angela for this gift! Learn more about Angela's work here.

In this episode, Naji talks with Rebecca Yeung, an accomplished leader who shares her journey and the wisdom encapsulated in her book, "What Rules?". The conversation starts with Rebecca recounting a pivotal choice during a challenging period in her life: accept misery or fight for change. This philosophy underpins her book, which challenges conventional expectations and societal "rules" that often guide people's lives and careers. Rebecca explains the inspiration behind the book's title, crediting her executive coach Gayle Grader, who helped her recognize that by not adhering to typical "rules," she was able to break through barriers like the "bamboo ceiling." This led to the exploration of six key rules in her book: the goals rule, strengths rule, opportunity rule, limits rule, either-or rule, and happiness rule. These rules prompt deeper reflection on what drives us, encourage embracing one's strengths, and challenge traditional success metrics. Throughout the episode, Rebecca discusses the importance of finding fulfillment and celebrating small wins along life's journey. She emphasizes that success is not solely defined by titles or wealth but by meaningful progress and continuous improvement. She also shares practical tips for leaders to help their teams grow by applying these principles in the workplace, fostering environments where individuals can thrive, develop, and find true joy in their work. Rebecca's insights offer a fresh perspective on redefining success, encouraging listeners to live authentically and find happiness in the present, rather than constantly pursuing elusive future goals. "Life is too short to live by someone else’s rules." MEET OUR GUEST Rebecca Yeung Corporate Vice President at FedEx Corporation. Rebecca Yeung is a Corporate Vice President at FedEx Corporation and leads Operations Science and Advanced Technology. In her role, she is responsible for driving critical aspects of FedEx’s innovation and transformation strategy including scaling up robotics and automation technology, autonomous vehicles, decision science, and electromobility. She sits on the FedEx Strategic Management Committee, a C-suite leadership group that sets the strategic direction for the enterprise. As an expert in both advanced technology and logistics operations, she frequently speaks at high profile industry forums including Fortune, World 50, Reuters Momentum, CES, The AI Summit-Silicon Valley, TechCrunch Mobility, HBS Tech Conference and MIT The Engine Tough Tech Summit. In March 2024, Rebecca was recognized by Reuters Events as one of the top 20 Trailblazing Women in Enterprise AI who are demonstrating real influence, impact, and leadership in large-scale enterprise AI deployment. Rebecca joined two public boards in 2023 – Royal Caribbean Group (NYSE: RCL) and Columbus McKinnon (NASDAQ: CMCO), bringing to both her technology and innovation expertise and strategic perspective. She has also previously served as a Board of Director for the Mid-South Food Bank between 2013 and 2022.

In this episode, I had the pleasure of speaking with Karim Benhadji, Chief Medical Officer at Inspirna. With nearly 20 years of experience in oncology drug development, Karim shared his journey from medical school in Algeria to his leadership roles in the biotech industry. He recounted how his passion for science and technology initially led him to medicine and eventually to oncology, a field that has seen transformative advancements over the past two decades. Karim’s experience spans various stages of drug development, including his pivotal role in the approval of key oncology drugs while serving at companies like Eli Lilly and Taiho Oncology. Karim emphasized the value of taking risks and embracing opportunities, which propelled his transition from academia to the pharmaceutical industry. He recounted how a recruiter’s unexpected call introduced him to clinical research at Eli Lilly, where he gained significant expertise in oncology drug development. Over the years, he led teams in both big pharma and smaller biotech environments, learning the importance of diversity, culture, and team collaboration. He shared his leadership philosophy of authenticity, humility, and empowering others, which has been integral to his success in building high-performing teams to develop life-saving therapies for cancer patients. As the conversation progressed, Karim highlighted the rapid advancements in oncology, especially the promise of precision medicine and cell-based therapies. He expressed optimism for the future, acknowledging the challenges but also celebrating the scientific progress that has given patients more treatment options. He also touched on the potential of artificial intelligence to revolutionize drug discovery and clinical trial processes, reinforcing his belief that while 90% of drug development efforts may not lead to immediate breakthroughs, they contribute invaluable knowledge to the field and ultimately drive innovation for patients. "It's all for the patients—they can't wait, and every day lost in bureaucracy or indecision impacts their lives." MEET OUR GUEST Karim Benhadji Chief Medical Officer at Inspirna. Karim Benhadji is currently Chief Medical Officer at Inspirna. He has nearly 20 years of experience in biopharmaceutical oncology drug development, and most recently served as Chief Medical Officer of GV20 Therapeutics. He previously served as Senior Vice President, Head of Clinical Development and Operations at Taiho Oncology where he oversaw the development of early and late phase portfolio assets, including the FDA approval of LYTGOBI® (futibatinib) in cholangiocarcinoma and the Phase 3 SUNLIGHT that led to the FDA approval of LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with metastatic colorectal cancer. Prior to joining Taiho Oncology, Karim spent 13 years with Eli Lilly and Company in oncology development roles of increasing responsibility, including overseeing several immuno-oncology programs. Dr. Benhadji received his M.D. from the University of Oran, and completed his Oncology fellowship in the universities of Oran and Paris. He also received a Master of Science in Pharmacology and Therapeutics in Oncology from the University of Paris.

In this episode, I had the pleasure of speaking with Suman Lal, whose journey from medical school in India to becoming a leader in innovation is as remarkable as it is unconventional. Initially embarking on a path toward medicine, Suman realized that his true passion lay beyond traditional medical practice. An encounter during medical school inspired him to explore other fields. This decision led him into research and ultimately to Singapore, where he found himself immersed in the country's burgeoning life sciences and healthcare innovation sector. While Suman experimented with various career paths — including academia and research — he discovered that his curiosity drove him to explore new industries rather than settle into any one role. Following his research phase, Suman transitioned into sales within the life sciences industry, a humbling experience that taught him valuable lessons in resilience and adaptability. He spent five years distributing products for early-stage companies, a role that honed his business acumen and led him to appreciate the practicalities of industry work. Afterward, he pursued an MBA at MIT Sloan, where he was drawn to Boston’s vibrant innovation ecosystem. Suman's post-MIT journey took him through several pivots, including starting a cosmetics startup, which introduced him to the world of drug discovery and eventually brought him back to Boston. His passion for innovation led him to the Cambridge Innovation Center (CIC), where he worked on building global innovation ecosystems. Suman’s current focus is on developing the Technology Innovation Studio (TINS), a "mini ecosystem" that combines physical space, curated networks, consulting, and innovation labs to accelerate breakthroughs in healthcare, life sciences, and beyond. With partnerships spanning MIT and CIC’s global network, Suman envisions TINS as a model for fostering collaboration between scientists, entrepreneurs, and investors to solve complex problems. His ambition is to replicate this model in innovation cities worldwide, creating a sustainable platform for innovation and learning that empowers individuals and communities alike. "Every challenge is an opportunity to create something better." MEET OUR GUEST Suman Lal is Managing Director of Technology Innovation Studio (TINS). Suman Lal is Managing Director of Technology Innovation Studio (TINS) - a physical space in Kendall Square that brings together business leaders, scientists, serial entrepreneurs, investors, industry experts, corporate innovation teams and policy experts to explore and apply tools, methods and models in innovation. Suman is also a Senior Advisor to the Cambridge Innovation Center (CIC) that operates innovation campuses and labs across cities in US, Europe and Asia, and in his previous role worked closely with the leadership team to advise diverse stakeholders in cities and regions around the world on building innovation infrastructure and ecosystems. Suman is also a Senior Advisor to the Venture Cafe Global Institute (VCGI) that operates the Venture Cafe gatherings in 15 cities, often described as the heartbeat of several innovation districts. Suman has deep experience in the area of technology commercialization, by making independent inventions, licensing intellectual property from major research institutions to form NewCos, and operating venture studios where he took interim CEO roles at the portfolio companies. Prior to this, Suman did technical sales and distribution for 15 early-stage companies over a 5 year period, gaining valuable insights into how early-stage companies transitioned into profitable and scalable businesses. Suman has an MD in clinical medicine and an MSc in human genetics and did his PhD in precision medicine & clinical pharmacology. Suman received his MBA from MIT as a Sloan Fellow, focusing on innovation and global leadership.

In this episode, my guest Diana Haydar shared her remarkable journey, growing up in Lebanon in a modest family amidst the complexities of war and the resilience it demanded. From her childhood, surrounded by her close-knit sisters, to the school memories we shared, it was clear how both the warmth of family and the trials of war shaped her. School debates and the realities of wartime Lebanon not only matured us beyond our years but also laid the foundation for her leadership journey. Despite the hardships, she drew strength from her experiences, which continue to fuel her resilience today. As a physiotherapist, she worked with children with special needs in Lebanon, confronting firsthand the struggles of families navigating a healthcare system that offered little support. Her compassion and drive led her to transition into a leadership role within the insurance industry, advocating for patient care and tackling the inequities in healthcare access. She recounted her experience managing teams, demonstrating how she embodied courage and commitment to serving those in need. Relocating to Dubai in 2021, she faced new challenges, but her determination and adaptability shone through. Reflecting on the stark contrasts between healthcare systems in Lebanon and the UAE, she emphasized her commitment to improving access and ensuring equitable healthcare. Her leadership is defined by resilience, purpose, and the ability to inspire her teams to push forward even in the face of adversity, underscoring a deep-rooted passion for making healthcare more accessible and fair for all. "Nothing can stop us from doing our job; we will never cease serving the people we are meant to serve." MEET OUR GUEST Diana Haydar, Director of Direct Sales at Nasco Insurance Group. Diana Haidar is the Director of Direct Sales at Nasco Insurance Group. Diana has been a key part of the Nasco Insurance group for 20 years, starting in Third Party Administration and then moving into the Direct Broker business, She now covers Middle East's direct portfolio, including Medical, General, and Life insurance. She started her career as a certified physiotherapist, then worked at a mountain Hospital with children with special needs . She holds also a master’s degree in Hospital and Health Management from ESCP & ESA . With 20 years of hands-on experience in the medical field as a professional as well as in insurance industry, Diana has been involved in various aspects of the business, from operations and sales to planning and growth. For over two decades, Diana has been empowering teams, encouraging fresh perspectives, and finding new ways for Nasco Middle East to grow in the world of direct sales. She's a leader dedicated to making a lasting impact on the insurance industry.

In this special episode in partnership with ESCP Business School, I’m joined by Jessica Leygues, an ESCP Business School MSc Biopharmaceutical Management alum, current General Secretary of the Women's Cancer Institute, for a thought-provoking conversation about her inspiring journey and her work redefining healthcare systems. Jessica, an engineer by training from AgroParisTech, shared her early career in biotech consulting and her transition to leadership roles, including as CEO of Medicen Paris Region during the height of the COVID-19 pandemic. She discussed how her experiences in the public and private sectors gave her insight into where real impact can be made in healthcare. Jessica emphasized that values-driven leadership and small teams have allowed her to focus on deep, meaningful change, particularly in her current project, building the Women's Cancer Institute from scratch. We explored her belief in co-constructing solutions alongside patients and teams, and how this approach is central to her leadership style. She noted the importance of fighting for what you believe in, balancing small victories, and ensuring inclusivity in decision-making. We also touched on the broader challenges in women's health, where systemic gaps, such as the underrepresentation of women in clinical trials, are leading to disparities in outcomes. Jessica's goal with the Women's Cancer Institute is to address these gaps with a holistic approach that includes personalized care, patient feedback, and a commitment to changing the cultural narratives around women's health. It was an inspiring conversation about leadership, innovation, and the future of healthcare, all driven by the belief that listening to people and co-creating solutions is the key to meaningful progress. "Fight for what you believe in" MEET OUR GUEST Jessica Leygues, General Secretary of Women’s Cancer Institute. Jessica Leygues is the General Secretary of Women’s Cancer Institute in France. Jessica is an engineer by training from AgroParisTech, and started her career at Alcimed consulting firm where she spent eight years developing new healthcare markets (Biotech/MedTech) for entrepreneurs, start-ups, SMEs and large corporations as well as for the public and semi-public innovation sector, including the French Ministry of Research, research institutes, competitiveness clusters and knowledge transfer centers. Strongly committed to optimization initiatives for healthcare systems, Jessica then joined Celgene, where she was responsible for a partnership hub aimed at developing the healthcare value model. In April 2020, the midst of COVID pandemic, Jessica became the CEO of Medicen Paris Region, Europe’s leading health cluster, where she redefined the strategic positioning of the group in order to launch concrete reindustrialization initiatives to accelerate growth in the French healthcare industry and boost national sovereignty to recover from the COVID-19 pandemic.

In this episode, we dive with Alison Fragale, a research psychologist, award-winning professor, international keynote speaker, and author, into the profound insights of understanding human behavior, especially for those of us in leadership positions. We explore how essential it is to recognize that at the core of any organization, it's the psychology of the people involved that really drives success. Alison highlights how often leaders, especially those with technical backgrounds, might overlook the importance of these human factors until they face significant challenges in getting people to move in the right direction. It's not just about the data or scientific narratives; it's about connecting with people on a level that influences their behavior. We also discuss the critical role of status and power in our lives and organizations. Status is about respect—how much we are valued by others—while power is about controlling resources that others care about. These two are closely linked, but they are distinct. Alison emphasizes that many people assume if they are powerful, they will automatically be respected. However, the reality is often the opposite; respect is the foundation that can lead to power. This understanding is particularly important when addressing issues like gender and minority status in the workplace, where ascribed characteristics can unfairly influence status. Tune-in to learn more in this incredible conversation with Alison, and don't hesitate to get her recently published book! "Be yourself in the most strategic way possible" MEET OUR GUEST Alison Fragale, a research psychologist, award-winning professor, international keynote speaker, and author. Alison Fragale, a research psychologist, award-winning professor, international keynote speaker, and author, on a mission to help others — especially women — work and live better by understanding and applying the science of people. Alison excels in translating her deep academic expertise is in status, power, negotiation, and influence into actionable advice. Alison is currently Professor at Kenan-Flagler Business School at the University of North Carolina and her research appeared in several news outlets such as Wall Street Journal, The Washington Post, The Boston Globe, to name a few…

In this special episode in partnership with ESCP Business School, I’m joined by Clarissa Gorin, a pharmacist and ESCP Business School MSc Biopharmaceutical Management alum, who transitioned from the blockchain industry to head Medical Affairs at Ad Scientiam, a MedTech company specializing in digital biomarkers. Clarissa shares her journey from a traditional pharmacy career path to embracing tech innovation in healthcare, particularly in the fight against counterfeit medicines in developing countries. Her work at Ad Scientiam, which originated from the Paris Brain Institute, focuses on creating digital biomarkers using smartphone sensors and AI to monitor and predict the progression of neurodegenerative diseases. Clarissa's unique perspective highlights the importance of adaptability and the practical application of technology to meet real-world needs in the healthcare sector. Throughout the episode, we dive into Clarissa's experiences in navigating cultural challenges in tech adoption, particularly in developing regions, and how this has shaped her approach to leading innovative projects. She emphasizes the value of understanding the specific needs of both patients and healthcare providers when developing new technologies, and the critical role that digital biomarkers and AI can play in the future of medical diagnostics and treatment. Clarissa also reflects on the importance of accessibility and humility in tech development, ensuring that solutions are not only high-tech but also practical and adaptable to diverse healthcare settings around the world. "Effective leadership hinges on adaptability and the ability to respond swiftly to change." MEET OUR GUEST Clarissa Gorin, Head of Medical Innovation, Medical Affairs at Ad scientam. Clarissa holds a dual degree in Pharmacy and a Master of Science (MSc) specialized in pharmaceutical and biotechnology management from ESCP Business School. She quickly developed a keen interest in emerging technologies, data management, and their applications in the healthcare sector. Following her initial professional experience focusing on the blockchain industry and the fight against counterfeit medicines in developing countries, Clarissa joined Ad Scientiam in 2020 as Head of Medical Affairs. Ad Scientiam, a MedTech company originating from the Paris Brain Institute, specializes in developing digital biomarkers that enable the monitoring and prediction of the progression of certain neurodegenerative pathologies and rare diseases. These innovative markers are derived from proprietary algorithms for measuring precise analysis movements, vocal activity, or image processing derived from smartphone sensors and AI technologies. Within Ad Scientiam, her role involves working collaboratively with the Scientific Board to ensure the development and validation of these biomarkers, leveraging her medical knowledge and expertise. 

In this episode, we had the pleasure of speaking with Carl Dahlberg, who shared his fascinating journey from a computer science nerd to an emergency physician and medical innovator. Carl discussed how his passion for problem-solving has driven his diverse career, spanning IT, financial trading, and emergency medicine. He reflected on his transition into healthcare and how his tech background influenced his approach to medicine, emphasizing creativity and innovation. Carl highlighted a recurring theme in his career: a desire to solve important problems for real people, which ultimately led him to focus on healthcare innovation. He expressed concerns about the U.S. healthcare system's inefficiencies and the need for a fundamental redesign to improve outcomes and reduce costs. When discussing his work mentoring entrepreneurs, Carl emphasized the importance of listening to customers and stakeholders to truly understand the problems that need solving. He also shared his insights on leadership, noting that modern leaders should align incentives and communicate the mission clearly to their teams, rather than merely issuing directives. In a reflective segment, Carl shared his views on concepts like innovation, entrepreneurship, health equity, and spreading joy in organizations. He underscored the importance of joy in work, distinguishing it from mere fun, and emphasized that true satisfaction comes from tackling meaningful challenges. Carl concluded with advice for healthcare leaders: ensure that clinicians, who are the embodiment of the mission, have a voice in decision-making processes to avoid potentially disastrous oversights. "True satisfaction comes from solving important problems for real people, not just making a profit." MEET OUR GUEST Carl Dahlberg, President at Dahlberg Healthcare Solutions. Carl Dahlberg, a physician innovator whose passion is solving important problems for real people.  Holding degrees from The University of Michigan Medical School and MIT Sloan School of Management Carl has a multifaceted background spanning technology, medicine, art and business.  He’s co-founder of the MIT Sloan Physicians Group and a mentor with the MIT Sandbox and UM6P Explorer innovation programs.  Carl blends medical proficiency with entrepreneurial spirit and relentless creativity to drive positive change in healthcare and beyond.

In this episode, Naji welcomes Emilia McLaughlin, a biotech founder and CEO, to discuss her journey into the field. Emilia shares that her initial interest in medicine led her to study biochemistry, but she eventually found her passion in parasitology. She describes her shift from academic research to entrepreneurship as motivated by a desire to directly impact patient care, which she found lacking in academic work. Emilia highlights her experience with the incubator program Entrepreneur First, which catalyzed her transition into biotech entrepreneurship. She emphasizes the importance of building strong teams, hiring the right people, and maintaining a focus on patient needs in the biotech industry. She discusses the challenges of being a female founder in a predominantly male industry and the importance of supporting other women in making the leap from academia to entrepreneurship. Throughout the conversation, Emilia emphasizes the value of bravery and risk-taking in entrepreneurship, particularly for women, and underscores the importance of keeping patients at the forefront of healthcare innovation. "Nobody has all the answers. You've just got to throw yourself in and do the best you can." MEET OUR GUEST Emilia McLaughlin, Founder and CEO at Kyron Bio. Emilia McLaughlin is founder and CEO of kyron.bio, a startup based in Paris dedicated to pioneering tomorrow’s therapeutics. Originally from London, Emilia moved to Paris in 2017 to pursue a PhD in parasite molecular biology at the Institut Pasteur. Upon completing her PhD, she founded kyron.bio with the aim of enhancing the efficacy of protein therapeutics through innovative glycan modifications. Since its inception, Emilia has successfully recruited a world-class scientific team, established a state-of-the-art laboratory, secured core technology IP, and garnered over €1.2M in competitive grants from the French government and the EU. Additionally, she has raised €1.1M in equity funding. Currently, the company is testing its first therapeutic in human serum and has developed a robust pipeline of innovative products. In 2024, Emilia was recognized as a Woman in Leadership by the European Innovation Commission. She is passionate about empowering women to take on leadership roles and supports academics who aspire to transition into entrepreneurship. 

In this episode, Naji talked with Anthony Dowidowicz, a physician leader with a background in engineering and emergency medicine, about the exciting potential of quantum computing in healthcare. Anthony explains how his fascination with quantum mechanics led him from engineering to medical school and eventually to become a physician leader. They delve into the power of quantum computing, its unique characteristics, and its potential applications in healthcare. Anthony highlights that while quantum computing won't replace classical computers, it excels in solving complex problems, making it invaluable in healthcare where vast amounts of data need to be processed. Throughout the discussion, Anthony stresses the importance of virtuous leadership in healthcare, urging leaders to prioritize patients' well-being over short-term profits and to advocate for the ethical and equitable use of technology in healthcare. "Quantum computing can make healthcare more equitable and personalized" MEET OUR GUEST Anthony Dowidowicz a physician executive. Dr. Anthony Dowidowicz is a physician executive who has served as a senior physician  leader of health systems  and health plans.  He is an emergency physician by background and is a graduate of the MIT Sloan school of management where he founded and coordinates the MIT Physician Leadership Group.   As an engineer and lifelong technology enthusiast, Dr. Dowidowicz’s professional interests include physician leadership, health system design, and emerging computing technologies.